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tion (WHO).ABSTRACT: Literature data relevant to the decision to allow a waiver of in vivo
bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage
forms containing doxycycline hyclate are reviewed. According to the Biopharmaceutics
Classification System (BCS), doxycycline hyclate can be assigned to BCS Class I. No
problems with BE of IR doxycycline formulations containing different excipients and
produced by different manufacturing methods have been reported and hence the
risk of bioinequivalence caused by these factors appears to be low. Doxycycline has a
wide therapeutic index. Further, BCS-based dissolution methods have been shown to
be capable of identifying formulations which may dissolve too slowly to generate
therapeutic levels. It is concluded that a biowaiver is appropriate for IR solid oral
dosage forms containing doxycycline hyclate as the single Active Pharmaceutical
Ingredient (API) provided that (a) the test product contains only excipients present
in doxycycline hyclate IR solid oral drug products approved in the International
Conference on Harmonization (ICH) or associated countries; and (b) the comparator
and the test products comply with the BCS criteria for ‘‘very rapidly dissolving’’ or,Correspondence to: D.M. Barends (Telephone: 31-30-
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two products are ‘‘rapidly dissolving.’’  2009 Wiley-Liss, Inc. and the American Pharmacists
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hyclate; permeability; regulatory science; solubilityFigure 1. Structure of doxycycline hyclate.INTRODUCTION
A biowaiver monograph for doxycycline hyclate
based on literature data, together with some
additional experimental data, is presented.
The risks of waiving in vivo bioequivalence (BE)
testing for the approval of new multisource and/or
reformulated immediate release (IR) solid oral
dosage forms containing doxycycline hyclate
are evaluated under consideration of its biophar-
maceutical and clinical properties. This eva-
luation refers to drug products containing
doxycycline hyclate, which is the hemiethanolate
hemihydrate form of doxycycline hydrochloride,
as the single Active Pharmaceutical Ingredient
(API). The purpose and scope of this series of
monographs have been previously discussed.1
Briefly, the aim of these monographs is to evaluate
all pertinent data available from literature
sources for a given API to assess the risks
associated with a biowaiver. For these purposes,
risk is defined as the probability of an incorrect
biowaiver decision as well as the consequences
of the decision in terms of public health and
individual patient risks. On the basis of these
considerations, a recommendation can be made as
to whether a biowaiver is advisable or not. This
systematic approach to recommend or advise
against a biowaiver decision is referred to in the
recently published World Health Organization
(WHO) Guideline.2 These monographs do not
intend to simply apply the WHO,2 US FDA,3
and/or EMEA Guidance,4 but aim to apply
these guidances and further serve as a critical
evaluation of these regulatory documents. Bio-
waiver monographs have already been published
for acetaminophen (paracetamol),5 acetazola-
mide,6 aciclovir,7 amitriptyline hydrochloride,8
atenolol,1 chloroquine (phosphate, sulfate, and
hydrochloride),9 cimetidine,10 diclofenac (sodium
and potassium),11 ethambutol dihydrochloride,12
ibuprofen,13 isoniazid,14 metoclopramide,15 pre-
dnisolone,16 prednisone,17 propranolol hydro-
chloride,1 pyrazinamide,18 quinidine sulfate,19
ranitidine hydrochloride,20 rifampicin,21 and
verapamil hydrochloride.1 They are also available
online at http://www.fip.org/bcs.22RMACEUTICAL SCIENCES, VOL. 99, NO. 4, APRIL 2010GENERAL CHARACTERISTICS
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1,11-dioxo - 2 -naphthacenecarboxamide
monohydrochloride, compound with ethyl
alcohol (2:1), monohydrate.27
Doxycycline hyclate is official in the JP XV28
where it is named ‘‘doxycycline hydrochloride
hydrate.’’ The Martindale26 uses the name ‘‘doxy-
cycline hydrochloride’’ for doxycycline hyclate.
The molecular weight of doxycycline hyclate is
512.9 and its melting point is 2018C.29 The structure
of doxycycline hyclate is shown in Figure 1.Therapeutic Indication and Dose
Doxycycline is bacteriostatic against a wide
variety of organisms, both Gram-positive andDOI 10.1002/jps
BIOWAIVER MONOGRAPH FOR DOXYCYCLINE HYCLATE 1641Gram-negative. It is used mainly for the treat-
ment of urinary tract, respiratory tract, and
gastrointestinal (GI) tract infections.30 The usual
initial dose of doxycycline is the equivalent of
200 mg doxycycline base (equal to 230.8 mg of
doxycycline hyclate) as a single dose or in divided
doses over the first day. This initial dose is
followed by 100 mg (equivalent to 115.4 mg of
doxycycline hyclate) daily.26 For children weigh-
ing less than 45 kg an initial dose of approximately
4 mg/kg/day followed by 2 mg/kg/day may be
given, whereby the effects of drug on teeth and
bones should be taken into consideration.26,30
In severe cases, for example, in patients with
sensitive gonococcal infections, a dosage of 200 mg
doxycycline is maintained throughout the course
of treatment.26 Occasionally, as in the case of
syphilis, a daily dose of 300 mg may be given for
15 days.26
According to the Essential Medicines List of
the WHO (EML, 15th ed., March 2007), 100 mg
doxycycline (hydrochloride) capsules or tablets
can be used as an antibacterial.31 In case of
malaria, 100 mg doxycycline as capsules (hydro-
chloride) or dispersible tablets (monohydrate) can
be used in combination with quinine for curative
treatment, and for malarial prophylaxis 100 mg
doxycycline (hydrochloride) capsules or tablets
can be prescribed.31Therapeutic Index and Toxicity
Doxycycline is considered to be a wide therapeutic
index drug according to the US FDA definition,32
and there is generally no need to monitor blood
levels. An LD50 of 262 mg/kg was reported in
rats.33 No serious adverse effects of doxycycline
have been reported. Disturbances of the GI tract
are commonly observed following oral adminis-
tration of tetracycline antibiotics in therapeutic
doses; however, doxycycline shows the least GI
adverse effects among the tetracycline antibio-
tics.26 On the other hand, of all the tetracycline
antibiotics, doxycycline hyclate, especially in
capsule form, is most likely to cause esophageal
ulceration.26,34–36 Doxycycline monohydrate
may be an alternative to doxycycline hyclate in
patients with high risk of suffering from esopha-
geal lesions because it has less acidic properties
than the hyclate salt.37
As for other tetracycline antibiotics, doxycycline
can accumulate in calcium-rich tissues such as
bones and teeth during their formation, and mayDOI 10.1002/jps JOcause yellow and brown discoloration and enamel
hypoplasia in developing teeth in children.26
Photosensitivity reactions (mostly phototoxic
and in rare cases photoallergic) due to accumula-
tion of doxycycline in the skin have also been
reported.30,38,39
In general, tetracycline antibiotics should not
be used in patients who have renal disease,
specifically, renal insufficiency or renal failure.
However, if therapy with a tetracycline proves
necessary for such a patient, doxycycline or
minocycline are preferred due to their minimal
renal clearance.26 Studies to date have indicated
that at usual recommended doses of doxycycline,
the drug does not accumulate in patients with
renal impairment.26,40
It is contraindicated to give doxycycline to
patients with porphyria.26,41
Symptoms including nausea, vomiting, and
diarrhea are commonly observed with overdosage
of tetracycline antibiotics including doxycycline.26
Occasionally, overdosage of doxycycline has led to
liver and kidney damage as well as pancreatitis.42
Treatment for overdosage with the oral prepara-
tion of doxycycline should be symptomatic and
gastric lavage may be considered.PHYSICOCHEMICAL PROPERTIES
Salt, Stereoisomers, and Polymorphs
Salts of doxycycline for pharmaceutical prepara-
tions listed in the pharmacopoeias include doxy-
cycline monohydrate (free base), doxycycline
hyclate (in some pharmacopoeias under the name
‘‘hydrochloride,’’ see above), and doxycycline
calcium.28,43–46 The USP 32 has monographs
for doxycycline monohydrate, doxycycline hy-
clate and doxycycline calcium, although the
latter salt is used only for oral solutions.43 The
European Pharmacopoeia (Ph.Eur., 5th ed.) has
monographs on doxycycline monohydrate and
doxycycline hyclate.44,46 The International Phar-
macopoeia (Ph.Int., 4th ed.),46 the British Phar-
macopoeia (BP 1993)45 as well as the Japanese
Pharmacopoeia (JP XV)28 include only doxycy-
cline hyclate. Oral products with Marketing
Authorizations (MAs) in Germany (DE),42 contain
either the hyclate or the monohydrate. This
monograph pertains only to the hyclate salt.
No polymorphism of doxycycline hyclate has
been reported.URNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 4, APRIL 2010
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Doxycycline hyclate is classified as soluble33 or
freely soluble44 in water. An aqueous solubility of
50 mg/mL has been reported, but without specify-
ing the temperature.47 Doxycycline hyclate
aqueous solution, containing 1% doxycycline,
has a pH of 2–3.43,48 Solubility of doxycycline
hyclate in SGFsp, pH 1.2 and in SIFsp, pH 6.8 at
room temperature was reported as about 40 and
28 mg/mL,49 corresponding to dose/solubility
(D/S) ratios of 5.77 and 8.24 mL (based on a
230.8 mg dose of doxycycline hyclate), respec-
tively. The values are far less than the D/S cut-off
of 250 mL for the ‘‘high solubility’’ biowaiver
criterion.2,3
To confirm the ‘‘high solubility’’ properties of
doxycycline hyclate, further experimental data for
doxycycline hyclate solubility in compendial
buffers pH 1.0, 1.2, 4.5, 6.8, and 7.5 were obtaineda
at 378C using the standard shake-flask method.50
The experiment was performed by adding
461.6 mg doxycycline hyclate powder, equivalent
to 400 mg doxycycline, to 250 mL buffer. In all
cases the powder went immediately into solution,
demonstrating that doxycycline hyclate has ‘‘high
solubility’’ at all five pHs representing the GI
conditions at 378C.Partition Coefficient
Log P values of 1.90 and 0.63 were reported for
doxycycline hyclate and doxycycline free base,
respectively.40,51 Calculations using fragmenta-
tion methods based on atomic contributions
to lipophilicity and by using the C log P pro-
gram (version 3.0, Biobyte Corp., Claremont, CA,
http://www.biobyte.com) yielded values of 0.60
(C log P) and 3.66 (log P).pKa
Doxycycline is an amphoteric compound with
three pKa values.
52,53 At 208C, pKa values of
3.5 (tricarbonyl system), 7.7 (ketophenolic sys-
tem), and 9.5 (dimethylammonium group) have
been reported.54aExperiments performed at the Institute of Pharmaceutical
Technology, Goethe University, Frankfurt am Main, Germany.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 4, APRIL 2010Dosage Form Strengths
Dosage form strengths of doxycycline are
expressed as mg free base. The WHO EML lists
100 mg doxycycline (capsules or tablets).31 Table 1
shows IR doxycycline hyclate tablets with MAs in
Germany (DE),42 Denmark (DK),55 Finland (FI),56
France (FR),57 the Netherlands (NL),58 Norway
(NO),59 Spain (ES),60 Sweden (SE),61 the United
Kingdom (UK),62 and the United States (US).63
These MAs cover a range of strengths correspond-
ing to 20, 50, 100, and 200 mg doxycycline base.PHARMACOKINETIC PROPERTIES
Absorption and Bioavailability
Among tetracycline antibiotics, doxycycline is
reported to have the best absorption.
The absolute bioavailability (BA) of doxycycline
administered orally at a dose of 100–200 mg is 90–
100%.30,40,64 The average percent fraction dox-
ycycline absorbed in humans ( Fa%) was reported
to be 95%.40 Doxycycline is rapidly absorbed; it
can be detected in the blood within 15 min of
administration.65 The absorption primarily occurs
in the duodenum.40 A secondary peak of doxycy-
cline in plasma is normally observed due to
enterohepatic cycling.37,66 Linear pharmacoki-
netics of orally administered doxycycline have
been demonstrated in the dose range 100–
600 mg.40 A peak plasma doxycycline concentra-
tion of about 2.6mg/mL is reached within approxi-
mately 2–3.5 h after a dose of 200 mg.26,40,42
Different salt forms demonstrated no significant
influences on doxycycline absorption.37,40,65
Unlike tetracycline, food only slightly reduces
the area under the plasma concentration–time
curve (AUC) and the mean plasma concentrations
of doxycycline.54,67,68 The mean serum concentra-
tions of doxycycline obtained during a multiple-
dosage regimen of 200 mg/day in the fasted and
fed states (regardless of the meal type) were found
to be in the therapeutic range (4.4mg/mL vs.
4.0mg/mL), indicating little or no clinical signifi-
cance of the food effect.67 Although milk and dairy
products reduce the exposure of several tetracy-
cline antibiotics significantly, this is not the case
for doxycycline.26 Dairy products have at most a
minor influence on doxycycline absorption.26
Nevertheless, it is recommended to take doxycy-
cline product separately from drugs containing di
and/or trivalent cations, for example, antacidsDOI 10.1002/jps
Table 1. Excipients Present in Doxycycline Hyclate IR Solid Oral Drug Products with a Marketing Authorization
(MA) in Germany (DE), Denmark (DK), Finland (FI), France (FR), the Netherlands (NL), Spain (ES), the United
Kingdom (UK) and the United States (US), and the Minimal and Maximal Amount of that Excipient Present Per
Dosage Unit in Solid Oral Drug Products with an MA in the US,y
Excipient
Drug Products Containing that Excipient
with an MA Granted by the Named Country
Range Present in Solid
Oral Dosage Forms with
an MA in the US (mg)
Acacia ES(1) 5–156a
Acetylated monoglycerides ES(2–4) 0.3–3.7
Alginic acid ES(5) NL(6) 32–80
Aluminium hydroxide DE(7,8) 15




Carnauba wax ES(1) NL(6,9) US (12,13) 0.15–58a
Castor oil hydrogenated DE(14) FI(15) 0.93–37.6a
Cellulose DE(14,16) ES(17–19) FR(20–23) NL(6,9,24–26)
UK (27) US (12,13,28–38)
4.6–1385a
Croscarmellose sodium DE(16) NL(9) US(12,13,28,30,31) 2–180
Crospovidone DE(39) DK(40) ES(41) FR(20,22,23) NL(42) 4.4–792a
Dimethicone FR(21) NL(25) 3.7
Ethylcellulose US(38) 1.0–121a
Furcellaran NL(25)




Hypromellose FR(21) NL(6,24,25) US(12,13,30,33,36,38) 0.8–537
Hypromellose phthalate ES(2,3) 13–104
Lactose DE(7,8,14,16,43) ES(1,5,10,11,18,19,45) FI(15)
FR(21) NL(6,9) US(12,13,31–36)
23–1020a
Macrogol DE(7,8,16,43) ES(18) FR (20,21,23) NL(24)
US(12,13,30,33–35)
0.12–500a
Magnesium stearate DE(7,8,14,16,43) ES(1,5,10,11,17–19,45) FI(15) FR(20–23)
NL(6,9,24–26) UK(27,44) US(12,13,28–38)
0.15–401a
Magnesium trisilicate ES(10,11) 20–77
Methylcellulose NL(9) US(33,34) 2.8–184
Polydextrose US(13) 3.8–8.1
Polysorbate 80 US(12,30) 2.2–418a
Poly(vinylalcohol) US(35) 0.7–20
Povidone ES(1–4) NL(6,9,25) 0.17–80
Propylene glycol NL(6,9,25) US(38) 1.5–52
Shellac ES(5) NL(9) UK(44) 4.4–25






Sodium lauryl sulphate ES(5) FR(20) NL(6) UK(44) US(29,30,37,38) 0.65–50
Sodium starch glycolate DE(14) NL(24) US(33,34) 2–876a
Starch DE(7,8,14,16,39) DK(40) ES(1–5,10,11,18,41)
NL(6,9,42) UK(44)
0.44–1135a
Stearic acid US (33,34) 0.9–72a
Sucrose DE(39) DK(40) ES(1–4,41) NL(42) 12–900
(Continued)
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Table 1. (Continued )
Excipient
Drug Products Containing that Excipient
with an MA Granted by the Named Country
Range Present in Solid
Oral Dosage Forms with
an MA in the US (mg)




(1) DOXICICLINA NORMON 100 mg Grageas. (2) DOXIPIL 100 mg cápsulas duras. (3) MEDEDOXI 50 mg cápsulas duras. (4)
PELEDOX 50. (5) VIBRACINA 100 mg cápsulas duras. (6) Doxycycline ratiopharm 100 mg, omhulde tabletten. (7) Aknefug1 Doxy
Filmtabletten (Mono). (8) Doxy-Wolff1 100/200 Filmtabletten (Mono). (9) Doxycycline 100, omhulde tabletten 100 mg. (10) Dosil,
cápsulas. (11) Dosil enzimático, cápsulas. (12) Doxycycline hyclate (doxycycline hyclate) tablet (100 mg), coated [Mutual Pharma-
ceutical Company, Inc.]. (13) Doxycycline hyclate (Doxycycline hyclate) tablet (20 mg), film coated [Mutual Pharmaceutical
Company, Inc.]. (14) Doxycyclin AL 100 T/200 T Tabletten (Mono). (15) Doximycin 100 mg/150 mg tabletti. (16) Doxycyclin
STADA1 100 mg/200 mg Filmtabletten (Mono). (17) DOXITEN BIO, cápsulas. (18) DOXITEN ENZIMÁTICO, cápsulas. (19)
RETENS1 cápsulas. (20) DOXY 100 mg cp pellic. (21) DOXYCYCLINE ARROW 100 mg cp pellic. (22) DOXYCYCLINE BIOGARAN
100 mg cp pellic séc. (23) SPANOR 100 mg cp pellic séc. (24) Doxycycline 100 PCH, omhulde tabletten 100 mg. (25) Doxycycline Lagap,
tabletten 100 mg. (26) Periostat 20 mg filmomhulde tabletten, filmomhulde tabletten. (27) PERIOSTAT1 20 mg film-coated tablets.
(28) Doxycycline (doxycycline hyclate) tablet (100 mg), coated [West-Ward Pharmaceutical Corp.]. (29) Doxycycline hyclate
(doxycycline hyclate) capsule (50/100 mg) [Watson Laboratories, Inc.]. (30) Doxycycline hyclate (doxycycline hyclate) tablet
(100 mg) [Watson Laboratories, Inc.]. (31) Doxycycline hyclate (doxycycline hyclate) capsule (50/100 mg) [Mutual Pharmaceutical
Company, Inc.]. (32) Doxycycline hyclate (doxycycline hyclate) capsule (50/100 mg) [West-ward Pharmaceutical Corp.]. (33)
Doxycycline hyclate (doxycycline hyclate) tablet (100 mg), film coated [IVAX Pharmaceuticals, Inc.]. (34) Doxycycline hyclate
(doxycycline hyclate) capsule (50/100 mg) [IVAX Pharmaceuticals, Inc.]. (35) Doxycycline hyclate (doxycycline hyclate) tablet
(20 mg), film coated [Lannett Company, Inc.]. (36) Periostat (doxycycline hyclate) tablet (20 mg) [CollaGenex Pharmaceuticals,
Inc.]. (37) Vibramycin hyclate (doxycycline hyclate) capsule (50/100 mg) [Pfizer Labs]. (38) Vibra-tabs (doxycycline hyclate) tablet
(100 mg), film coated [Pfizer Labs]. (39) Antodox1 100 mg/200 mg Hartkapseln (Mono). (40) Doxycycline ‘‘Ethypharm,’’ kapsler,
hårde. (41) PRODERMA 50 mg/100 mg/200 mg cápsulas duras. (42) Ethypharm doxycycline 50 mg/100 mg/200 mg, capsules.
(43) Doxy 200 mg Kapseln (Mono). (44) Doxycycline capsules 50, 100 mg (Actavis UK, Ltd). (45) DOXICICLINA VALOMED.
Colorants, flavors, and ingredients present in the printing ink are not included. Coating substances are excluded if in the SmPC
the constituents of core and coating are stated separately.
Excluded are: soft gelatin capsules filled with a solution and oral suspensions.
Sources of data: see text, Dosage Form Strengths Section.
FDA’s Inactive Ingredient Database, http://www.fda.gov/cder/iig/iigfaqWEB.htm #purpose (version date 11-01-2009).
aThe upper range value reported is unusually high for solid oral dosage forms and the authors doubt its correctness.
1644 JANTRATID ET AL.since the absorption of doxycycline may be
impaired.69Permeability
An apparent permeability coefficient (Papp) of
doxycycline of 17.5 106 cm/sec using the Caco-2
monolayer system was reported.70 In the same
study a high permeability internal standard
suggested by the US FDA,3 antipyrine, demon-
strated a Papp of 45.3 106 cm/sec.70 By compar-
ing the drug permeability between Caco-2 and
PAMPA assay, it was demonstrated that trans-
cellular but not paracellular permeation is the
main transport pathway of doxycycline.70Distribution
The volume of distribution of doxycycline at
steady-state (Vdss ) varies between approximately
53 and 134 L and the volume of the central
compartment (Vc) is 22 L.
40 These values can varyJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 4, APRIL 2010slightly according to the doxycycline salt.65 In the
elderly, the volume of distribution is higher than
in young patients.71 Doxycycline distributes
effectively into the body tissues especially liver,
kidneys, and digestive tract.26,40 Doxycycline
as well as other tetracycline antibiotics can be
retained at the sites of new bone formation and
impair calcification in developing teeth, and in
some injured soft tissues.26 The plasma protein
binding of doxycycline is the highest among
tetracycline antibiotics, between 80% and 95%
at usual therapeutic concentrations.26,40,42Metabolism and Excretion
No problems with instability of doxycycline in the
GI tract have been reported.
Although it has been demonstrated that no
metabolites of doxycycline are found in blood,
urine, or feces,40 some reference sources indicate
that some metabolism does occur.42,71,72 Addi-
tionally, a decrease in the area under the plasmaDOI 10.1002/jps
BIOWAIVER MONOGRAPH FOR DOXYCYCLINE HYCLATE 1645concentration–time curve (AUC) of doxycycline
was observed during concomitant treatment with
drugs that induce hepatic enzymes, for instance,
alcohol (chronic use), rifampicin, carbamazepine,
phenobarbital, phenytoin, and primidone, owing
to the increased metabolism of doxycycline.26,73
Doxycycline is slowly eliminated via the kid-
neys to an extent of approximately 30–40% in
patients with normal renal function.26,40 A renal
clearance of 1.8–2.1 L/h was reported.40 The rest
of the dose is eliminated through the digestive
tract and excreted in the feces, probably due
to partial biliary elimination in addition to
diffusion through the intestinal wall and sub-
sequent chelation with the metal ions, for
example, Ca2þ, Mg2þ present in the small intes-
tine.26,40 The nonchelated doxycycline is reab-
sorbed and undergoes enterohepatic cycling.26,40
The elimination half-life (t1/2b) of doxycycline
varies from about 12 to 25 h 26,40,42,74,75 after
single dosing and between 17 and 24 h after
multiple dosing.76 These values do not change in
the elderly patients although the serum and
tissue concentrations are higher than those
observed in young adults.40 In renal failure
patients, the t1/2b and AUC remain unchanged
and no accumulation is observed even after
repeated doses in anuric patients.40 At first
glance, these results appear to be inconsistent
with renal elimination as the major route of
doxycycline elimination. However, a decrease in
the fraction of doxycycline bound to plasma
proteins in renal failure patients appears to result
in an increase in nonrenal clearance, which then
compensates for the decrease in renal clearance.77DOSAGE FORM PERFORMANCE
Bioavailability and Bioequivalence
Several reports in the literature have demon-
strated BE of doxycycline products.37,65,67,74,75,78–87
The study details, BE criteria, and results of
the pharmacokinetic studies conducted from 1975
to 2007 are summarized in Table 2. All studies
reported the pharmacokinetic parameters
between doxycycline hyclate products, various
doxycycline salt forms and different dosage forms
of doxycycline to be ‘‘bioequivalent’’ or ‘‘not
significantly different.’’ It should be noted that
doxycycline can be regarded as a borderline
‘‘highly variable drug’’ based on the data from
Kitzes-Cohen et al.86 Indeed, the Central Labora-DOI 10.1002/jps JOtory of German Pharmacists proposed using a
95% confidence interval (CI) and an acceptance
range of 70–130% to assess BE.88 Nevertheless,
most studies showed that the 90% CI of the
AUC and Cmax of the multisource products lay
within the 80–125% range of those of the
comparator.Excipients
Table 1 shows the excipients present in IR
doxycycline hyclate products with an MA in a
large number of countries. In view of their MAs, it
may be supposed that most of these drug products
successfully had passed an in vivo BE study. In
this respect, the regulatory authorities of DE
classified doxycycline an API for which in vivo BE
testing is required,89 but in NL doxycycline was,
and still is, exempted from in vivo BE studies for
national MAs.90 For other countries no such
information was available and hence it is not
possible to judge which products had actually
passed an in vivo BE study. However, due to their
MAs, and hence use in clinical practice, it is
concluded that the risk of excipients listed in
Table 1 exerting a significant effect on the extent
and rate of absorption of doxycycline is probably
small.
No study directly investigating the influence of
excipients on the absorption of doxycycline has
been reported in the literature. However, studies
on the effects of antacids and drugs that can
modify the GI environment on doxycycline
absorption have been reported.91 These results
can indirectly be applied to the excipients having
similar characteristics, since the same influence
on doxycycline absorption can be anticipated.
A randomized, crossover study conducted by
Deppermann et al.91 investigated the influence of
antacids on the BA of doxycycline. The antacid
studied contained 900 mg of aluminum hydroxide
(Al(OH)3) and 600 mg of magnesium hydroxide
(Mg(OH)2) per dose. The results of this study
indicated that antacids, such as a mixture of
Al(OH)3 and Mg(OH)2, lead to subtherapeutic
serum levels of doxycycline. Administration of
doxycycline after antacid treatment resulted in
approximately 85% reduction in absorption, lead-
ing to a relative BA of only 15%. The ability of
doxycyline to form chelates with metal ions such
as Fe2þ, Al3þ, Ca2þ, Zn2þ, and Mn2þ was used to
explain the results. The second part of the same
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1648 JANTRATID ET AL.which investigated the possible influence of
pirenzepine, an antimuscarinic drug, and raniti-
dine, an H2-receptor antagonist, on the BA of
doxycycline. These two drugs modified the GI
tract conditions, with pirenzepine changing the
motility and ranitidine increasing the upper
GI pH. No changes in Cmax and AUC were
observed either with pirenzepine or ranitidine
coadministrations, although the Tmax was pro-
longed in both cases. It was concluded that
physical interactions via chelation rather than
changes in the GI environment are responsible for
the decrease in the BA of doxycycline when
administered with antacids.Dissolution
According to the USP 32,43 the same dissolution
test conditions are used for doxycycline hyclate
capsules and doxycycline hyclate tablets: USP
Apparatus 2 (paddle method), rotational speed
75 rpm, 900 mL water as a dissolution medium,
temperature 378C. The dissolution specification
for the capsules is ‘‘not less than 80% (Q) dissolves
within 30 min’’ and for the tablets is ‘‘not less than
80% (Q) dissolves within 90 min.’’43 The Ph.Int.
4th ed. describes the dissolution test conditions
for doxycycline capsules and doxycycline tablets
as: paddle method, rotational speed 75 rpm,
500 mL pH 6.8 buffer as a dissolution medium,
temperature 378C.48 The dissolution specification
for both tablets and capsules is ‘‘not less than
80% (Q) dissolves within 30 min.’’48
Recently, dissolution of five marketed doxycy-
cline hyclate IR products in DE was tested using
both the WHO and the US FDA ‘‘BCS-conform’’
methods.50 The dissolution test conditions con-
sisted of the paddle method, medium volume
500 mL, rotational speed 75 rpm (WHO)2 or
50 rpm (US FDA),3 and temperature 378C. The
products were tested in three different dissolution
media: SGFsp—pH 1.2; acetate buffer—pH 4.5;
and SIFsp—pH 6.8. The results indicated that
in vitro BE evaluation based on the WHO test
procedure is more appropriate than the US FDA3
testing method and that in vitro BE evaluation
based on comparative dissolution testing tends
to be over-discriminating compared to in vivo
evaluation, as some products that had success-
fully passed an in vivo BE evaluation failed to pass
the in vitro BE evaluation.
Using the static pellet method to assess the
dissolution performance of the hyclate and otherJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 4, APRIL 2010salt forms of doxycycline in various media at 258C
it was found that the hyclate form is less sensitive
to the common ion effect than the other salts.92
Insensitivity to the common ion effect of doxycy-
cline hyclate in terms of dissolution is important,
especially for in vivo dissolution in the GI tract,
due to the high chloride level in the human gastric
juice, and thus justifies the widespread use of this
salt form in doxycycline oral dosage forms.DISCUSSION
Solubility
Doxycycline hyclate is ‘‘highly soluble’’ according
to all BCS criteria2,3 and no solubility problems in
the upper GI milieu are expected.Permeability and Absorption
Doxycycline hyclate is ‘‘highly permeable’’ accord-
ing to all BCS criteria2,3 since the BA of doxy-
cycline is nearly complete following oral
administration.40 Caco-2 studies support this
classification.70Risks Associated with Biowaiving
With any positive biowaiver decision there is,
statistically speaking, a risk that the decision
reached is incorrect. Therefore the risk of reach-
ing such an incorrect decision needs to be
assessed. Risk is defined as the combination of
the probability of occurrence of harm and the
severity of that harm.93 Therefore, the overall risk
of a positive biowaiver decision can be defined
as the probability that the test product, after
passing the surrogate BE testing, is actually
bioinequivalent and the therapeutic consequences
for the patient, if such a situation should occur.
Each of these possibilities is discussed below.Probability of Occurrence of Bioinequivalence
One report has identified an effect of antacids on
the BA of doxycycline.91 Seemingly contradictory
to this finding, two doxycycline hyclate products
with an MA in DE contain Al(OH)3, see Table 1,
however, the amount of Al(OH)3 present in these
drug products is likely far lower than used in the
study cited. No other reports of BE problems were
identified and hence it can be concluded thatDOI 10.1002/jps
BIOWAIVER MONOGRAPH FOR DOXYCYCLINE HYCLATE 1649doxycycline hyclate, formulated in solid IR dosage
forms, appears to exhibit very little risk in terms
of bioinequivalence. This is in line with its BCS
Class I classification.Probability of False Positives of Surrogate BE Testing
Comparative dissolutionb testing, especially
based on the WHO method,2 appears to assure
detection of bioinequivalence caused by poor
in vivo disintegration and in vivo dissolution,
should such an unlikely situation arise.
Although comparative dissolution testing will
not elucidate excipients and formulation effects
on the absorption of doxycycline, the ‘‘highly
permeable’’ characteristic of doxycycline hyclate
combined with lack of excipient effects on BE
would indicate that excipient effects on perme-
ability are unlikely. By using only excipients
which are listed in Table 1 in the formulation, the
probability of occurrence of an excipient effects on
permeability is further reduced.Patient’s Risks Associated with Bioinequivalence
Doxycycline hyclate has a wide therapeutic index
and is mainly used as an antibacterial and for
prophylaxis of malaria.31 Moreover, according to
the draft ‘‘Science-based criteria for BE in vivo
and in vitro, biowaivers, and strategic framework
for implementation’’ of the Pan American
Health Organization,94 doxycycline is classified
as having ‘‘Intermediate Health Risk,’’ which
basically means that when the plasma concentra-
tions of doxycycline are outside the therapeutic
window, adverse (but not necessary serious)
reactions may occur.94
However, the risk that a bioinequivalent drug
product could be formulated, and the further risk
that this product would pass all the criteria for
accepting BE on the basis of in vitro data, and yet
give rise to supra- or subtherapeutic plasma
levels, or a Cmax different from the comparator,
is minimal.CONCLUSION
A biowaiver for IR solid oral dosage forms
containing doxycycline hyclate is scientifically
justified, provided that the test product containsbFalse positives defined as: a bioinequivalent drug product
being declared bioequivalent.
DOI 10.1002/jps JOonly excipients present in a number of doxycycline
hyclate IR solid oral drug products approved
in ICH or associated countries, for instance as
presented in Table 1; and that both the test and
comparator products either (a) are both ‘‘very
rapidly dissolving,’’ or (b) are both ‘‘rapidly
dissolving’’ with similarity of the dissolution
profiles demonstrated at pH 1.2, 4.5, and 6.8, as
described in the WHO test procedure.2 When not
all of these conditions can be fulfilled, BE should
be established on the basis of in vivo pharmaco-
kinetic study.ACKNOWLEDGMENTS
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doxycycline. Lancet 2:1155.
73. Garraffo A, Dellamonica P, Fournier JP, Lapalus P,
Bernard E. 1988. The effect of rifampicin on the
pharmacokinetics of doxycycline. Infection 16:297–
2298.
74. Gschwend MH, Martin W, Erenmemisoglu A,
Scherm M, Dilger C, Tamur U, Kanzik I, Hincal
AA. 2007. Pharmacokinetics and bioequivalence
study of doxycycline capsules in healthy male sub-
jects. Arzneimittelforschung 57:347–351.
75. Kees F, Dehner R, Dittrich W, Raasch W, Grobecker
H. 1990. Untersuchungen zur Bioverfugbarkeit von
Doxycyclin. Arzneimittelforschung 40:1039–1043.
76. Fenner R. 2000. Arzneistoffe, 3rd edition. Stutt-
gart: Deutscher Apotheker Verlag. pp 61-62.
77. Houin G, Brunner F, Nebout T, Cherfaoui M,
Lagrue G, Tillement JP. 1983. The effects of chronic
renal insufficiency on the pharmacokinetics of
doxycycline in man. Br J Clin Pharmacol 16:245–
252.
78. Antal EJ, Jaffe JM, Poust RI, Colaizzi JL. 1975.
Bioequivalency of doxycycline products. J Pharm
Sci 64:2015–2018.
79. Hampel B, Lode H, Fenner H, Gikalov I. 1980.
Doxycyclin-Pellets: eine wirkstoffgerechte Darrei-
chungsform mit gesicherter Bioäquivalenz. Arznei-
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valenz einer optimierten Doxycyclin-Zubereitung.
Arzneimittelforschung 39:1162–1165.
83. Saano V, Paronen P, Peura P. 1990. Bioavailability
of doxycycline from dissolved doxycycline hydro-
chloride tablets—Comparison to solid form hydro-
chloride tablets and dissolved monohydrate tablets.
Int J Clin Pharmacol Ther Toxicol 28:471–
474.
84. Balogh A, Rechenbach C, Brix R, Mundhenke J,
Tjuljumbow R, Hoffmann A. 1991. Untersuchungen
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